QUICK LINKS



Uncovering the Genetic Mechanisms of Common Language Disabilities
Read more »
Sign up for updates & info:
Name:  
Email:

GlaxoSmithKline and NIEHS Researchers use HelixTree's Recursive Partitioning as Part of Pharmacogenetic Genome-Wide Scan

* The following is a citation and abstract from The Pharmacogenomics Journal.


Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan.

The Pharmacogenomics Journal (2007) 7, 180-189. doi:10.1038/sj.tpj.6500414; published online 12 September 2006

L L Warren ¹, A R Hughes ¹, E H Lai ¹, D V Zaykin ² , S A Haneline ¹, A T Bansal ³, A W Wooster ¹, W R Spreen ¹, J E Hernandez ¹, T R Scott ¹, A D Roses ¹ and M Mosteller ¹ on behalf of the CNA30027 and CNA30032 study teams

  1. 1 GlaxoSmithKline, RTP, NC, USA
    2 National Institute of Environmental Health Sciences, RTP, NC, USA
    3 GlaxoSmithKline, Harlow, Essex, UK

Correspondence: Dr M Mosteller, Genetic Analysis, Genetic Research, GlaxoSmithKline, Five Moore Drive, RTP, NC 27709, USA. E-mail: mike.m.mosteller@gsk.com

Received 28 February 2006; Revised 13 July 2006; Accepted 24 July 2006; Published online 12 September 2006.

Abstract
The objective of pharmacogenetic research is to identify a genetic marker, or a set of genetic markers, that can predict how a given person will respond to a given medicine. To search for such marker combinations that are predictive of adverse drug events, we have developed and applied two complementary methods to a pharmacogenetic study of the hypersensitivity reaction (HSR) associated with treatment with abacavir, a medicine that is used to treat HIV-infected patients. Our results show that both of these methods can be used to uncover potentially useful predictive marker combinations. The pairwise marker combination method yielded a collection of marker pairs that featured a spectrum of sensitivities and specificities. Recursive partitioning results led to the genetic delineation of multiple risk categories, including those with extremely high and extremely low risk of HSR. These methods can be readily applied in pharmacogenetic candidate gene studies as well as in genome-wide scans.

About Golden Helix, Inc.
Founded in 1998 in Bozeman, MT, Golden Helix is a leading provider of data analysis software products and services designed to accelerate life science research and increase pharmaceutical R&D productivity. The company's products enable hundreds of researchers at the world's top pharmaceutical, biotech and non-profit research organizations to discover the genes that cause disease, improve target and lead discovery processes, and advance pharmacogenetic initiatives. Its products have been cited in nearly 100 peer reviewed publications that detail ground-breaking research for discovering the genetic and environmental basis of disease and creating safer and more effective medicines.
Golden Helix is committed to Accelerating the Quest for Significance.
For more information, please visit www.goldenhelix.com.

###

Media Contact:
Josh Forsythe
Director of Marketing
Golden Helix, Inc.
406-585-8137 x202
jlforsythe[at]goldenhelix.com

© 2015 Golden Helix, Inc | Looking for the Golden Helix Institute or Symposia? Facebook Twitter Linked In Blog YouTube

| Site Map| Citing| Privacy Policy| Contact Us